154 related articles for article (PubMed ID: 28940056)
1. Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
Hou J; Wang S; Zhang Y; Fan D; Li H; Yang Y; Ge F; Hou W; Fu J; Wang P; Zhao H; Sun J; Yang K; Zhou J; Li X
Ann Hematol; 2017 Dec; 96(12):2005-2013. PubMed ID: 28940056
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
3. Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
Zhao H; Zhao Y; Zhang Y; Hou J; Yang H; Cao F; Yang Y; Hou W; Sun J; Jin B; Fu J; Li H; Wang P; Ge F; Zhou J
Ann Hematol; 2018 Mar; 97(3):409-416. PubMed ID: 29289982
[TBL] [Abstract][Full Text] [Related]
4. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
[TBL] [Abstract][Full Text] [Related]
5. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide.
Jin B; Zhang Y; Hou W; Cao F; Lu M; Yang H; Tian X; Wang Y; Hou J; Fu J; Li H; Zhou J
J Cancer Res Clin Oncol; 2020 Feb; 146(2):485-492. PubMed ID: 31686248
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone.
Hou W; Zhang Y; Jin B; Cao W; Lu M; Yan L; Yang H; Tian X; Hou J; Fu J; Zhao H; Li H; Zhou J
Blood Cells Mol Dis; 2019 Nov; 79():102351. PubMed ID: 31400712
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia - A retrospective clinical study.
Ge F; Zhang Y; Cao F; Li J; Hou J; Wang P; Li H; Xu M; Liu S; Li L; Li X; Wang S; Lv C; Su Y; Zhou J
Hematology; 2016 Jun; 21(5):287-94. PubMed ID: 26871996
[TBL] [Abstract][Full Text] [Related]
10. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.
de la Serna J; Montesinos P; Vellenga E; Rayón C; Parody R; León A; Esteve J; Bergua JM; Milone G; Debén G; Rivas C; González M; Tormo M; Díaz-Mediavilla J; González JD; Negri S; Amutio E; Brunet S; Lowenberg B; Sanz MA
Blood; 2008 Apr; 111(7):3395-402. PubMed ID: 18195095
[TBL] [Abstract][Full Text] [Related]
11. Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
Wang Y; Hou W; Li H; Tian X; Li J; Hu T; Shi D; Zhang Y
Ann Hematol; 2022 May; 101(5):1039-1047. PubMed ID: 35174404
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
17. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
Chen X; Fan S; Zhao Y; Zhou J
Clin Transl Oncol; 2021 Oct; 23(10):2171-2180. PubMed ID: 33942222
[TBL] [Abstract][Full Text] [Related]
18. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
Huang H; Qin Y; Xu R; You X; Teng R; Yang L; Xu M; Liu H
Leuk Res; 2012 Jul; 36(7):841-5. PubMed ID: 22534100
[TBL] [Abstract][Full Text] [Related]
20. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
